DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1640)

Venous Thromboembolism | Unmet Need | Detailed, Expanded Analysis (US & EU)

Venous Thromboembolism | Unmet Need | Detailed, Expanded Analysis (US & EU)

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Coming August 2018


Venous thromboembolism (VTE), comprising of deep vein thrombosis (DVT) and pulmonary embolism (PE), represents a significant medical and economic burden. Although, the launch of the NOACs signifies an important milestone for the treatment and secondary prophylaxis of VTE, there are still some areas of unmet need that remain underserved in this patient population. This report examines current treatment performance against treatment goals in the treatment and secondary prophylaxis of DVT and PE from the perspective of emergency room physicians and hematologists. This report also offers insight from these physicians on existing unmet needs for DVT and PE; while our target product profile conjoint simulator demonstrates how various attributes influence these physicians’ prescribing decisions.


  • What are the treatment drivers and goals for VTE?
  • What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key treatment drivers and goals for VTE?
  • What are the prevailing areas of unmet need and opportunity in VTE?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European [[physician type, plural]] for a hypothetical new VTE drug?


Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 31 European emergency room physicians and hematologists fielded in May 2018

Key companies: Bayer, Pfizer, Bristol-Meyer Squibb, Boehringer Ingelheim, Daiichi Sankyo, Janssen Pharmaceuticals

Key drugs: Pradaxa, Xarelto, Eliquis, Savaysa/Lixiana

Coming soon
  • Pub Date: August 2018
  • Author(s): Shreya Saxena, MBA

Request report

Recent reports:
You may also be interested in: